If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
September 2010
Vol 1 • iSSue 3
pathways
THE CLINICAL TRIALS NETWORK NEWSLETTER
The Radiotracer Approval Bottleneck:
Improving the Flow through the Pipeline
Henry F. VanBrocklin, PhD
Table of
Contents
2 CTN Workshop 2011
3 2010 AM Highlights
4 FDG Summit
Summary
IRHG Summary
NOPR Study: NaF-18
PET
5 Reconsidering NaF-18
Course Curriculum
6 Tech Research Tip
CTN Education
Experience
Vital Sign
Measurements
8 Save-the-Date
Over the past 10–20 years, there has been
a dramatic proliferation of genomic and pro-
teomic data with a concomitant increase in
the number of therapeutic and imaging tar-
gets. However, this intensified activity in
therapeutic drug and imaging agent research
has yet to fi
September 2010 Vol 1 • iSSue 3 pathways
Radiotracer approval Continued from page 1.
Highlights from the Clinical Trials Network Sessi
What’s Happening Worldwide Standardization of FDG
BIOMARKER SpoTlIGHT reconsiDeringtHe useFulness
Tech Talk ctn eDucation exPerience Rebecca Sajda
Radiotracer approval Continued from page 2. IND
Society of Nuclear Medicine 1850 Samuel Morse Dri